PROHANCE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prohance, and when can generic versions of Prohance launch?
Prohance is a drug marketed by Bracco and is included in two NDAs.
The generic ingredient in PROHANCE is gadoteridol. One supplier is listed for this compound. Additional details are available on the gadoteridol profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PROHANCE?
- What are the global sales for PROHANCE?
- What is Average Wholesale Price for PROHANCE?
Summary for PROHANCE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Clinical Trials: | 9 |
| Patent Applications: | 655 |
| Drug Prices: | Drug price information for PROHANCE |
| What excipients (inactive ingredients) are in PROHANCE? | PROHANCE excipients list |
| DailyMed Link: | PROHANCE at DailyMed |
Recent Clinical Trials for PROHANCE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Alabama at Birmingham | Early Phase 1 |
| University of Alabama at Birmingham | Phase 1 |
| Bracco (Sponsor) | Phase 4 |
Pharmacology for PROHANCE
| Drug Class | Paramagnetic Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
US Patents and Regulatory Information for PROHANCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bracco | PROHANCE MULTIPACK | gadoteridol | INJECTABLE;INJECTION | 021489-001 | Oct 9, 2003 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PROHANCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| Bracco | PROHANCE | gadoteridol | INJECTABLE;INJECTION | 020131-001 | Nov 16, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PROHANCE
See the table below for patents covering PROHANCE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2604796 | ⤷ Sign Up | |
| Japan | S6452764 | 1-SUBSTITUTED 1,4,7-TRISCARBOXYMETHYL-1,4,7,10- TETRAAZACYCLODODECANE AND ANALOGUE | ⤷ Sign Up |
| Canada | 1296715 | 1-(SUBSTITUANT)-1,4,7-TRIS(CARBOXYMETHYL)-1,4,7,10- TETRAAZACYCLODODECANE ET COMPOSES ANALOGUES (1-SUBSTITUTED-1,4,7-TRISCARBOXYMETHYL-1,4,7,10- TETRAAZACYCLODODECANE AND ANALOGS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
